Investigation of longlasting inhibition of the serotonin transporter in the human brain using functional imaging (fMRI) - SERT-fMRT

Bundesinstitut für Arzneimittel und Medizinprodukte0 个研究点目标入组 30 人开始时间: 2022年2月14日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Written informed consent for the study
•- Age restriction: 18-50 years
•- Healthy to mildly impaired general health (ASA-Physical Status Classification (ASA 1-2), Haynes et Lawler 1995).
•- BMI above 18 kg/m2
•- Diagnosis of an affective disorder (Hamilton > 8) and new prescription of oral antidepressant therapy with an SSRI (for patients)
•- No prescription of an SSRI within 9 months before the start of the study
•- No prescription of any other antidepressant agent within 9 months before the start of the study (also includes opripamol, pregabalin, and St. John's wort preparations).

•- For women: Pregnancy or lactation period
•- Severe other acute or chronic illness, reduced general health ASA-Physical Status Classification (ASA 3-6)
•- Substance-related addictive disorders
•- Psychoses
•- Metal implants in the body (e.g. pacemaker, copper coil in women)
•- Wearing metallic (magnetic) and non-removable jewelry, tattoos, or cosmetics
•- Strong fear of confined spaces (claustrophobia)
•- Insufficient command of the German language for the processing of questionnaires
•- Regular intake of other medications (except L-thyroxine, oral contraceptives, statins, ACE inhibitors)
•- Regular intake of anticoagulant drugs, especially phenprocoumon (Marcumar), and of NSAIDs (especially acetylsalicylic acid) 2 weeks before the start of the study
•- Existing suicidality

发起方